1. Home
  2. Research
  3. Research Groups
  4. Multiple Sclerosis

Multiple Sclerosis

2024 Activity indicators

  • 1 European competitive project: IMI 3-TR
  • 4 national public competitive projects/networks: ISCIII, MICINN
  • 13 private projects led
  • 33 clinical studies led 
  • 2 HR competitive contracts
  • 36 publications
  • IF: 166.60
  • Q1 publications: 21 (58%)
  • D1 publications: 6 (17%)
  • 1 thesis
  • 1 award
  • National public agency evaluators: 1 PI
  • Members of editorial committees: 2 PI
  • 1 patent in Spain P202390028 from European validation EP20382988, which protects predictive biomarkers of autoimmunity for treatment with Alemtuzumab in patients with multiple sclerosis.
  • 1 new Spanish patent P202390028 based on European validation EP20382988 protecting predictive biomarkers of autoimmunity for treatment with Alemtuzumab in patients with multiple sclerosis.
  • 1 new European patent application EP23383037.1 for predictive biomarkers of response to ocrelizumab treatment in patients with multiple sclerosis with PCT/EP2024/078404
  • 1 new intellectual property registration CC-BY-ND-NC with reference 2306134577905 to protect an app for monitoring multiple sclerosis patients
  • 1 biomarker panel for ultra-sensitive detection of biomarkers, protected by know-how, in use
  • 1 paper on new diagnostic criteria and 1 paper on new biomarkers 
  • 4 visitors hosted and 2.1 months stay:
    • UPM
    • Hospital Virgen de la Arrixaca
    • Hospita de Santiago de Compostela

Milestones

  1. Implementation of the use in clinical practice of the ideal combination of serum biomarkers to predict progression of flare-associated or flare-independent disability in Multiple Sclerosis (MS) (Brain; PMID: 39101570).
  2. Determination of normal MS biomarker values to study modification with currently approved highly effective drugs in MS. Their value in predicting optimal/suboptimal response to such drugs is demonstrated (4 articles (Q1): PMID: 39063050, 39224593, 39606235, 39684862).
  3. Coordination of the multiple sclerosis area in the European 3TR project (IMI) and a target in the RICORS of inflammation (translation of biomarkers to clinical practice). Award of two competitive public projects led by young researchers of the group: AES24 (PI24/01018) & European project EIT-Health.
  4. The group leads the IRYCIS Scientific-Technical Service "Precision Immunological Markers", in which we provide biomarker detection service to research personnel and participate in research projects with different pharmaceutical companies, which has provided an income of more than 300,000.00 €.
  5. Development of a mobile app for patients, which allows passive and remote monitoring of the risk of disability progression (PMID: 38598952, 39246042). Award of the EMCARE European project of the EIT-Health program (Deep Tech Venture Builder program call 2025) that will allow accelerating its development and creating a Spin-Off for its exploitation.

Bibliometrics

  Articles Accum. IF Mean IF Articles Q1 or Q2  % in Q1 or Q2 Articles D1 % in D1
2020 27 110.61 4.10 24 89 3 11
2021 38 315.39 8.30 26 68 10 26
2022 30 151.34 5.04 25 83 1 3
2023 28 156.53 6.52 19 68 5 18
2024 36 166.62 5.04 32 89 6 17
  159 900.48 5.80 126 79 25 16

* Only original articles, editorial material, guidelines and reviews.

Networks and alliances